Enanta Pharma (ENTA) Misses Q4 EPS by 27c

Enanta Pharma (NASDAQ: ENTA) reported Q4 EPS of $1.86, $0.27 worse than the analyst estimate of $2.13. Revenue for the quarter came in at $75.9 million versus the consensus estimate of $73.12 million.

Financial Guidance for Fiscal Year Ending September 30, 2018

• Research and development expense between $90 million and $110 million
• General and administration expense between $22 million and $28 million

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Wintermar acquires full control of Fast Offshore Supply, adding 5 new CTVs
• Stifel Starts Victrex Plc. (VCT:LN) (VTXPF) at Buy